Posted in | News | Nanorobotics

Tauriga Initiates Steps to Develop Bacterial Robot for Nuclear Energy Production Industry

Tauriga Sciences Inc. ("Tauriga" or "the Company"), a diversified company focused on generating profitable revenues through license agreements and the development of a proprietary technology platform in the nanorobotics space, has today obtained a detailed chemical profile and analysis of effluent discharged from a major United States ("U.S.") based nuclear power plant (pressurized water reactor).

This is an important first step in developing a customized bacterial robot for the nuclear energy production industry. The effluent discharge pertaining to nuclear power plants is defined as liquid waste and pollutants discharged into the surface of a surrounding body of water (i.e. rivers, lakes, seas, or oceans). In the process of generating electricity, nuclear power plants utilize hundreds of thousands of gallons of water per minute to cool the plant systems. The internal Liquid Waste Disposal System ("LWDS") of a power plant is constructed to detect, remove, collect, store, process and transfer all liquid waste for controlled release into the surrounding body of water within the limits of Federal Regulation 10CFR20 during normal operations. The treatment and processing of effluent discharge is both a major operating cost for the nuclear plants and a source of friction within environmental agencies and activists.

On October 29, 2013 Tauriga announced a comprehensive Strategic Alliance with Cincinnati, Ohio-based Bacterial Robotics LLC and its wastewater-to-value subsidiary, Pilus Energy. The Agreement stipulates the formation of a Joint Venture Partnership ("JVP") for the development and commercialization of a nuclear power industry specific Bacterial Robot, or BactoBot(TM). The Company plans to incorporate the chemical profile of the effluent into its whitepaper on the feasibility of engineering a BactoBot prototype ("NuclearBot") to potentially treat and remediate such wastewater. The next step will be to work with Novel Device Lab ("NDL") at University of Cincinnati and its director, Dr. Jason Heikenfeld ("Dr. Heikenfeld"), to develop a strategy for rapid-prototyping. On October 31, 2013 Tauriga announced that Dr. Heikenfeld was appointed as the 3rd member of the Company's scientific advisory board.

In addition, the Company is actively compiling information to accurately estimate the potential market size of the addressable market defined as cleaning and remediation of nuclear power plant effluent. Compilation of such estimates will include all cost variables, such as: storage costs, filtration systems, monitoring and detection technologies, discharge of water, dilution of contaminated water, and municipal fines and penalties. The Company is also working diligently to identify the practical application(s) of its NuclearBot, should the Company be successful in developing a working prototype. Once the company is comfortable with its estimate of the addressable market size and the corresponding technology application(s), shareholders will be notified through a press release.

Tauriga's CEO Seth M. Shaw commented, "The Company has established a roadmap for rapidly developing the BactoBot technology based on initially identifying the puzzle to solve, then building a prototype, followed by practical application of such technology. Obtaining the chemical profile of nuclear power plant effluent enables the Company to move forward with development work and now our laboratory partners can incorporate an effective game plan."

Press release avilable from http://www.globenewswire.com/

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.